Drugmaker Stada Said to Talk to Buyout Firms in €8 Billion Sale

Stada Arzneimittel AG has begun talking to potential buyers as the German generic-drug maker’s owners pursue a possible sale that could value the company at about €8 billion ($8.7 billion), people with knowledge of the matter said.

The early-stage suitors include Clayton Dubilier & Rice, CVC Capital and KKR & Co., the people said, declining to be identified because the information is private. Other firms looking at the business include GTCR, Canada Pension Plan Investment Board, Asia-based investment firm Hillhouse, Nordic Capital and Koch Industries, some of them said.

Stada’s management last week began ...